Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003311 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
NCT00003311: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00003311 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 19 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003311, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of different regimens of combination chemotherapy in treating patients with newly diagnosed mantle cell lymphoma.
Interventions
- DRUG cyclophosphamide
- DRUG dexamethasone
- BIOLOGICAL filgrastim
- DRUG doxorubicin hydrochloride
- DRUG cytarabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 1998-05-20 |
| Est. Completion | 2007-04-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003311
The ClinicalTrials.gov registry entry for NCT00003311 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00003311 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003311 about?
NCT00003311 is a clinical study titled "Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of different regimens of combination chemotherapy in treating patients...
What is the current status of trial NCT00003311?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 1998-05-20. Estimated completion is 2007-04-18.
What interventions are being tested in trial NCT00003311?
The interventions under investigation include: cyclophosphamide (DRUG), dexamethasone (DRUG), filgrastim (BIOLOGICAL), doxorubicin hydrochloride (DRUG), cytarabine (DRUG).
Who is sponsoring clinical trial NCT00003311?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.